Clinical Trial Update: JSKN003 in Platinum-Resistant, Relapsed Epithelial Ovarian Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update for JSKN003 in platinum-resistant, relapsed epithelial ovarian cancer; the study is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• JSKN003

Snippet

Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd | Conditions: Ovarian Cancer, Primary Peritoneal | Phase 3 | Status: NOT_YET_RECRUITING